FreeMind's Managing Partner's presentation at the National Academies of Science UIDP conference discussing Industry Academic collaborations in research and development and funding to such collaborations through non-dilutive funding sources.
A webinar by Ayal Ronen, M.Sc. - Senior Director Marketing and Sales at Freemind group. The webinar discusses recent non-dilutive funding opportunities supporting biodefense and infectious diseases research and development efforts.
Non dilutive R&D funding – mainly multibillion programs of Federal agencies – has become a major player in the life science finance industry. Today more than ever, NIH, DOD, NSF, CDC and dozens of other agencies, both federal and private, support biological and medical preclinical and clinical activities in all fields and scopes of research and development.
Non dilutive funding is available for every conceivable kind of research or development effort, whether it is an academic or industry project. Government agencies, as well as state organizations and private foundations, release daily hundreds of different solicitations covering topics that are of interest to public health and medical and life science research.
Over the last decade, many academic institutions established specialized centers that articulate their expertise in specific fields. These centers have the advantage of highly specialized human and physical resources. By virtue of their specifically defined purpose, they bring together the top experts in the field, working in proximity to each other for mutually beneficial and especially productive research.
Over the past decade, the United States government has allocated nearly $55 billion on preparing the nation against biological threats. The Obama administration has maintained that momentum with a total biodefense budget of $6.05 billion for FY2010, going primarily to the NIH and DOD. Additional civilian biodefense funds have been budgeted to the DHS, USDA, EPA, NSF and Department of State.
One of the most common misperceptions relating to non-dilutive funding for life science R&D is that the SBIR/STTR program is the main and even only funding resource available for the life science industry.
FreeMind Group is the lead consultancy firm for governmental grant identification and application assistance for Biotechnology Industry Organization (BIO) members
Our designated knowledge of non dilutive funding, on the one hand, and our numerous connections with the industry
The decision to use non-dilutive funding to support the R&D efforts of a company’s pipeline is often a strategic one.
